茴香酰化纤溶酶原链激酶激活剂复合物及其他溶栓药物在动物和人体中的药代动力学特性。 - Suppr

Suppr

超能文献

Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.

作者信息

Nunn B, Esmail A, Fears R, Ferres H, Standring R

机构信息

Beecham Pharmaceuticals Research Division, Great Burgh, Epsom.

出版信息

Drugs. 1987;33 Suppl 3:88-92. doi: 10.2165/00003495-198700333-00013.

DOI:10.2165/00003495-198700333-00013

PMID:3315618

Abstract

摘要

相似文献

Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.茴香酰化纤溶酶原链激酶激活剂复合物及其他溶栓药物在动物和人体中的药代动力学特性。

Drugs. 1987;33 Suppl 3:88-92. doi: 10.2165/00003495-198700333-00013.

Development of anisoylated plasminogen-streptokinase activator complex from the acyl enzyme concept.基于酰基酶概念研发茴香酰化纤溶酶原-链激酶激活剂复合物。

Semin Thromb Hemost. 1989 Apr;15(2):129-39. doi: 10.1055/s-2007-1002695.

Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.茴香酰化纤溶酶原链激酶激活剂复合物的临床前药理学评价

Drugs. 1987;33 Suppl 3:33-50. doi: 10.2165/00003495-198700333-00005.

Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.酰化纤溶酶原-链激酶激活剂复合物：溶栓治疗的新方法。

Pharmacotherapy. 1990;10(2):115-26.

Anistreplase for acute coronary thrombosis.阿尼普酶用于急性冠状动脉血栓形成。

Med Lett Drugs Ther. 1990 Feb 23;32(812):15-6.

Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.对急性心肌梗死患者使用茴香酰化纤溶酶原链激酶激活剂复合物和链激酶的血液学影响。IRS II研究中期报告。

Drugs. 1987;33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.

Intravenous bolus application of streptokinase and of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Clinical and haemostaseological findings.链激酶和茴香酰化纤维蛋白溶酶原链激酶激活剂复合物静脉推注用于急性心肌梗死。临床和血液学检查结果。

Drugs. 1987;33 Suppl 3:183-5. doi: 10.2165/00003495-198700333-00031.

Evaluation of the efficacy and safety of anisoylated plasminogen streptokinase activator complex in early myocardial infarction. Preliminary results.茴香酰化纤溶酶原链激酶激活剂复合物在急性心肌梗死中的疗效与安全性评估：初步结果

Drugs. 1987;33 Suppl 3:186-8. doi: 10.2165/00003495-198700333-00032.

[Effect of thrombolytic agents on infarct size and left ventricle systolic function in myocardial infarction].[溶栓药物对心肌梗死梗死面积及左心室收缩功能的影响]

Arch Mal Coeur Vaiss. 1990 Feb;83 Spec No 1:31-6.

[Effects of anistreplase on coronary patency in acute myocardial infarction].[茴香酰化纤溶酶原链激酶激活剂复合物对急性心肌梗死冠状动脉通畅的影响]

Arch Mal Coeur Vaiss. 1990 Feb;83 Spec No 1:25-9.

引用本文的文献

Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.开发抗止血剂的生化和分子基础的最新见解：综述

Indian J Clin Biochem. 2004 Jan;19(1):122-8. doi: 10.1007/BF02872406.

Pharmacokinetic optimisation of the treatment of embolic disorders.栓塞性疾病治疗的药代动力学优化

Clin Pharmacokinet. 1995 Jan;28(1):67-92. doi: 10.2165/00003088-199528010-00006.

Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.茴香酰化纤溶酶原链激酶激活剂复合物的临床前药理学评价

Drugs. 1987;33 Suppl 3:33-50. doi: 10.2165/00003495-198700333-00005.

A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.链激酶和茴香酰化纤溶酶原链激酶激活剂复合物在急性心肌梗死中的药代动力学特性比较。

Br J Clin Pharmacol. 1991 Feb;31(2):143-7. doi: 10.1111/j.1365-2125.1991.tb05502.x.

本文引用的文献

THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION.尿激酶作为一种溶栓剂的研发。通过静脉输注在人体中维持持续的溶栓状态。

J Lab Clin Med. 1965 May;65:713-31.

Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.人外源性（组织型）纤溶酶原激活剂在兔体内的周转率。

Thromb Haemost. 1981 Oct;46(3):658-61.

Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.重组DNA技术生产的组织型纤溶酶原激活剂在进展性心肌梗死患者中的临床药理学。

Circulation. 1985 Jan;71(1):110-6. doi: 10.1161/01.cir.71.1.110.

High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.急性心肌梗死中链激酶大剂量、短疗程静脉输注：对循环系统影响的描述

Am J Cardiol. 1986 Jun 1;57(15):1220-6. doi: 10.1016/0002-9149(86)90192-x.

[Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].

Klin Wochenschr. 1986 Aug 1;64(15):682-7. doi: 10.1007/BF01712052.

Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.静脉注射氨甲环酸纤溶酶原-链激酶激活剂复合物（BRL 26921）在急性心肌梗死中的临床疗效和动力学特性

Int J Cardiol. 1986 Apr;11(1):53-61. doi: 10.1016/0167-5273(86)90199-3.

Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.

Ann Intern Med. 1986 Mar;104(3):345-8. doi: 10.7326/0003-4819-104-3-345.

Thrombolytic therapy in the eighties.八十年代的溶栓疗法。

Blood. 1986 Jun;67(6):1529-41.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验